NasdaqGS:BIIBBiotechs
Biogen (BIIB) Valuation Check After Q4 Beat And Momentum In New Drugs Like Leqembi
Biogen (BIIB) is back in focus after its fourth quarter results topped Wall Street expectations, with newer drugs such as Leqembi and other recent launches helping offset pressure on older multiple sclerosis treatments.
See our latest analysis for Biogen.
The share price has responded to the recent earnings beat and product updates with a 16.07% 90 day share price return and a 43.30% 1 year total shareholder return, although longer term total shareholder returns over three and five years...